Aaron Michels
Concepts (322)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetes Mellitus, Type 1 | 62 | 2024 | 3360 | 7.570 |
Why?
| Autoantigens | 15 | 2022 | 397 | 3.670 |
Why?
| Receptors, Antigen, T-Cell | 14 | 2023 | 632 | 3.600 |
Why?
| Insulin | 27 | 2021 | 2162 | 3.470 |
Why?
| Islets of Langerhans | 15 | 2023 | 739 | 2.880 |
Why?
| Autoantibodies | 20 | 2023 | 1335 | 2.530 |
Why?
| T-Lymphocytes | 12 | 2023 | 1774 | 2.210 |
Why?
| Antineoplastic Agents, Immunological | 4 | 2022 | 156 | 2.170 |
Why?
| Programmed Cell Death 1 Receptor | 4 | 2019 | 197 | 1.890 |
Why?
| Insulin-Secreting Cells | 9 | 2022 | 330 | 1.740 |
Why?
| Hypoglycemic Agents | 9 | 2020 | 1032 | 1.720 |
Why?
| CD4-Positive T-Lymphocytes | 14 | 2021 | 984 | 1.670 |
Why?
| Autoimmunity | 13 | 2022 | 831 | 1.520 |
Why?
| Antibodies, Monoclonal | 5 | 2020 | 1284 | 1.470 |
Why?
| Autoimmune Diseases | 5 | 2019 | 398 | 1.310 |
Why?
| Insulin Antibodies | 4 | 2017 | 101 | 1.280 |
Why?
| Peptides | 6 | 2023 | 879 | 1.240 |
Why?
| Histocompatibility Antigens Class II | 7 | 2018 | 355 | 1.160 |
Why?
| HLA-DQ Antigens | 7 | 2019 | 176 | 1.120 |
Why?
| Immunologic Factors | 3 | 2019 | 225 | 1.090 |
Why?
| HLA-DR Antigens | 3 | 2022 | 224 | 1.040 |
Why?
| Melanoma | 2 | 2022 | 664 | 0.970 |
Why?
| Antigen Presentation | 2 | 2018 | 194 | 0.970 |
Why?
| Protein Precursors | 3 | 2021 | 126 | 0.930 |
Why?
| B7-H1 Antigen | 3 | 2021 | 144 | 0.900 |
Why?
| Cell Cycle Checkpoints | 2 | 2020 | 87 | 0.870 |
Why?
| Immunotherapy | 7 | 2021 | 493 | 0.860 |
Why?
| Models, Immunological | 2 | 2015 | 94 | 0.860 |
Why?
| Peptide Fragments | 6 | 2016 | 702 | 0.840 |
Why?
| Methyldopa | 2 | 2019 | 8 | 0.830 |
Why?
| Humans | 74 | 2024 | 118972 | 0.820 |
Why?
| HLA Antigens | 3 | 2022 | 230 | 0.800 |
Why?
| HLA-DQ beta-Chains | 1 | 2020 | 61 | 0.740 |
Why?
| Polyendocrinopathies, Autoimmune | 2 | 2010 | 18 | 0.720 |
Why?
| Health Fairs | 1 | 2019 | 9 | 0.710 |
Why?
| Disease Susceptibility | 1 | 2021 | 331 | 0.710 |
Why?
| Interferon-gamma | 2 | 2021 | 736 | 0.710 |
Why?
| Stevens-Johnson Syndrome | 2 | 2019 | 34 | 0.700 |
Why?
| Antigens | 4 | 2018 | 320 | 0.700 |
Why?
| Preventive Medicine | 1 | 2018 | 39 | 0.640 |
Why?
| Proinsulin | 2 | 2017 | 48 | 0.620 |
Why?
| Alleles | 5 | 2022 | 832 | 0.610 |
Why?
| Antibody Formation | 1 | 2018 | 276 | 0.580 |
Why?
| Influenza, Human | 1 | 2022 | 554 | 0.580 |
Why?
| Child | 27 | 2022 | 19129 | 0.570 |
Why?
| Dried Blood Spot Testing | 1 | 2016 | 68 | 0.570 |
Why?
| Immunity, Cellular | 1 | 2018 | 270 | 0.560 |
Why?
| Major Histocompatibility Complex | 2 | 2013 | 220 | 0.520 |
Why?
| Rituximab | 1 | 2016 | 155 | 0.520 |
Why?
| Graft Rejection | 1 | 2018 | 555 | 0.510 |
Why?
| Adolescent | 24 | 2021 | 18480 | 0.500 |
Why?
| Hypoglycemia | 3 | 2016 | 400 | 0.500 |
Why?
| HLA-D Antigens | 1 | 2014 | 36 | 0.500 |
Why?
| Lymphocyte Activation | 4 | 2020 | 1067 | 0.500 |
Why?
| Diet Therapy | 1 | 2014 | 38 | 0.500 |
Why?
| Protein Kinase Inhibitors | 1 | 2020 | 811 | 0.500 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 4 | 2019 | 51 | 0.490 |
Why?
| Drug Hypersensitivity | 1 | 2015 | 83 | 0.490 |
Why?
| Addison Disease | 1 | 2014 | 39 | 0.480 |
Why?
| Adrenal Glands | 1 | 2014 | 72 | 0.480 |
Why?
| Biomarkers | 3 | 2021 | 3588 | 0.480 |
Why?
| Mass Screening | 3 | 2019 | 1052 | 0.470 |
Why?
| Hormone Replacement Therapy | 1 | 2014 | 80 | 0.460 |
Why?
| Antibodies | 1 | 2015 | 392 | 0.460 |
Why?
| Disease Progression | 6 | 2021 | 2490 | 0.450 |
Why?
| Blood Glucose | 4 | 2024 | 1939 | 0.450 |
Why?
| Mice, Inbred NOD | 7 | 2018 | 574 | 0.440 |
Why?
| Prediabetic State | 1 | 2015 | 234 | 0.430 |
Why?
| Diabetic Ketoacidosis | 3 | 2020 | 168 | 0.400 |
Why?
| Genetic Predisposition to Disease | 7 | 2021 | 2275 | 0.400 |
Why?
| Organophosphorus Compounds | 1 | 2011 | 76 | 0.390 |
Why?
| Female | 35 | 2022 | 61564 | 0.390 |
Why?
| Glycine | 1 | 2011 | 162 | 0.390 |
Why?
| Young Adult | 16 | 2021 | 10793 | 0.390 |
Why?
| Male | 32 | 2022 | 57801 | 0.380 |
Why?
| Epitopes | 4 | 2021 | 443 | 0.380 |
Why?
| Carcinoma, Papillary, Follicular | 1 | 2010 | 8 | 0.370 |
Why?
| Struma Ovarii | 1 | 2010 | 7 | 0.370 |
Why?
| Animals | 21 | 2023 | 33381 | 0.370 |
Why?
| Immunosuppressive Agents | 1 | 2014 | 681 | 0.370 |
Why?
| Macromolecular Substances | 1 | 2010 | 201 | 0.370 |
Why?
| Endocrine System Diseases | 1 | 2010 | 32 | 0.360 |
Why?
| Adult | 27 | 2023 | 31512 | 0.350 |
Why?
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2022 | 310 | 0.350 |
Why?
| C-Peptide | 5 | 2016 | 137 | 0.340 |
Why?
| Child, Preschool | 13 | 2021 | 9491 | 0.330 |
Why?
| Transcription Factor 7-Like 2 Protein | 2 | 2018 | 24 | 0.320 |
Why?
| Haplotypes | 3 | 2020 | 473 | 0.320 |
Why?
| Neoplasms | 2 | 2020 | 2179 | 0.320 |
Why?
| Carbamazepine | 2 | 2019 | 19 | 0.310 |
Why?
| Inflammation | 2 | 2017 | 2566 | 0.310 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2020 | 2174 | 0.310 |
Why?
| CD8-Positive T-Lymphocytes | 3 | 2021 | 702 | 0.310 |
Why?
| Middle Aged | 20 | 2022 | 27617 | 0.310 |
Why?
| Pediatrics | 1 | 2015 | 985 | 0.300 |
Why?
| Glutamate Decarboxylase | 4 | 2017 | 159 | 0.300 |
Why?
| Infant | 9 | 2022 | 8293 | 0.290 |
Why?
| Blood Glucose Self-Monitoring | 2 | 2024 | 534 | 0.280 |
Why?
| Antilymphocyte Serum | 2 | 2016 | 66 | 0.270 |
Why?
| Granulocyte Colony-Stimulating Factor | 2 | 2016 | 70 | 0.270 |
Why?
| History, 21st Century | 2 | 2018 | 170 | 0.260 |
Why?
| Ovarian Neoplasms | 1 | 2010 | 420 | 0.260 |
Why?
| History, 20th Century | 2 | 2018 | 281 | 0.250 |
Why?
| Pluripotent Stem Cells | 2 | 2022 | 65 | 0.250 |
Why?
| Protein Binding | 3 | 2021 | 1975 | 0.230 |
Why?
| Hybridomas | 3 | 2020 | 233 | 0.230 |
Why?
| Mice | 11 | 2023 | 15520 | 0.230 |
Why?
| Lipodystrophy, Congenital Generalized | 1 | 2023 | 1 | 0.230 |
Why?
| Lipodystrophy | 1 | 2023 | 18 | 0.220 |
Why?
| CD3 Complex | 2 | 2020 | 92 | 0.220 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 827 | 0.200 |
Why?
| T-Lymphocytes, Regulatory | 2 | 2022 | 359 | 0.200 |
Why?
| Histocompatibility Antigens | 1 | 2021 | 102 | 0.200 |
Why?
| Insulin, Regular, Human | 1 | 2020 | 32 | 0.190 |
Why?
| Glucagon-Like Peptides | 1 | 2020 | 22 | 0.190 |
Why?
| Rhizotomy | 1 | 2000 | 3 | 0.190 |
Why?
| Polyethylene Glycols | 2 | 2016 | 578 | 0.190 |
Why?
| Virus Diseases | 2 | 2015 | 198 | 0.190 |
Why?
| Molecular Sequence Data | 3 | 2015 | 2871 | 0.190 |
Why?
| Clinical Trials as Topic | 2 | 2018 | 969 | 0.190 |
Why?
| Brachial Plexus | 1 | 2000 | 29 | 0.190 |
Why?
| Polymorphism, Single Nucleotide | 2 | 2018 | 2062 | 0.180 |
Why?
| Retroviridae | 1 | 2020 | 89 | 0.180 |
Why?
| Histocompatibility Antigens Class I | 1 | 2021 | 177 | 0.180 |
Why?
| Case-Control Studies | 3 | 2022 | 3171 | 0.180 |
Why?
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2019 | 7 | 0.180 |
Why?
| Muscle Spasticity | 1 | 2000 | 53 | 0.180 |
Why?
| Diagnostic Techniques, Endocrine | 1 | 2019 | 14 | 0.180 |
Why?
| Immunoassay | 1 | 2020 | 101 | 0.180 |
Why?
| Blood Specimen Collection | 1 | 2019 | 34 | 0.180 |
Why?
| Arm | 1 | 2000 | 106 | 0.180 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 453 | 0.170 |
Why?
| Stem Cells | 2 | 2021 | 559 | 0.170 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 667 | 0.170 |
Why?
| HLA-DRB1 Chains | 1 | 2019 | 97 | 0.170 |
Why?
| Prognosis | 2 | 2018 | 3443 | 0.170 |
Why?
| T-Lymphocytes, Cytotoxic | 1 | 2019 | 158 | 0.170 |
Why?
| Genotype | 2 | 2015 | 1882 | 0.170 |
Why?
| Models, Molecular | 2 | 2015 | 1435 | 0.160 |
Why?
| Cell Line, Transformed | 1 | 2018 | 136 | 0.160 |
Why?
| Transglutaminases | 2 | 2016 | 143 | 0.160 |
Why?
| Tissue Donors | 2 | 2021 | 336 | 0.160 |
Why?
| High-Throughput Screening Assays | 1 | 2019 | 122 | 0.160 |
Why?
| Treatment Outcome | 5 | 2019 | 9342 | 0.160 |
Why?
| Community Health Services | 1 | 2019 | 212 | 0.150 |
Why?
| Genetic Heterogeneity | 1 | 2017 | 56 | 0.150 |
Why?
| Antibodies, Viral | 1 | 2021 | 542 | 0.150 |
Why?
| Treatment Failure | 1 | 2018 | 341 | 0.150 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2016 | 26 | 0.150 |
Why?
| Radioimmunoassay | 1 | 2016 | 165 | 0.150 |
Why?
| Mutation | 3 | 2015 | 3457 | 0.150 |
Why?
| Amino Acid Sequence | 3 | 2017 | 2071 | 0.140 |
Why?
| Luminescence | 1 | 2016 | 34 | 0.140 |
Why?
| Genetic Variation | 1 | 2021 | 926 | 0.140 |
Why?
| Mice, Transgenic | 2 | 2019 | 2025 | 0.140 |
Why?
| Administration, Oral | 1 | 2018 | 756 | 0.140 |
Why?
| Dideoxynucleosides | 1 | 2015 | 20 | 0.140 |
Why?
| Donor Selection | 1 | 2016 | 73 | 0.130 |
Why?
| Luminescent Measurements | 1 | 2016 | 72 | 0.130 |
Why?
| Immunologic Memory | 1 | 2017 | 313 | 0.130 |
Why?
| Antigen-Presenting Cells | 1 | 2015 | 156 | 0.130 |
Why?
| Abatacept | 1 | 2014 | 42 | 0.130 |
Why?
| Monocytes | 2 | 2016 | 513 | 0.130 |
Why?
| Sequence Homology, Amino Acid | 1 | 2015 | 372 | 0.120 |
Why?
| Vitamin B Complex | 1 | 2014 | 37 | 0.120 |
Why?
| Pharmacogenetics | 1 | 2015 | 151 | 0.120 |
Why?
| Niacinamide | 1 | 2014 | 70 | 0.120 |
Why?
| Multifactorial Inheritance | 1 | 2015 | 143 | 0.120 |
Why?
| B-Lymphocytes | 1 | 2019 | 770 | 0.120 |
Why?
| Early Medical Intervention | 1 | 2014 | 56 | 0.120 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2014 | 102 | 0.120 |
Why?
| Chromogranin A | 1 | 2013 | 40 | 0.120 |
Why?
| CD4 Antigens | 1 | 2013 | 126 | 0.120 |
Why?
| Immunoconjugates | 1 | 2014 | 89 | 0.110 |
Why?
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 44 | 0.110 |
Why?
| Colorado | 2 | 2021 | 4196 | 0.110 |
Why?
| Secondary Prevention | 1 | 2014 | 227 | 0.110 |
Why?
| Aged | 5 | 2021 | 19657 | 0.110 |
Why?
| Diabetes Mellitus | 1 | 2021 | 942 | 0.110 |
Why?
| Interleukin-10 | 1 | 2015 | 306 | 0.110 |
Why?
| Myeloid Cells | 1 | 2014 | 128 | 0.110 |
Why?
| Incidence | 1 | 2019 | 2424 | 0.110 |
Why?
| alpha 1-Antitrypsin | 1 | 2014 | 115 | 0.110 |
Why?
| Multiprotein Complexes | 1 | 2014 | 149 | 0.110 |
Why?
| Celiac Disease | 1 | 2016 | 267 | 0.110 |
Why?
| Amino Acid Motifs | 1 | 2013 | 200 | 0.110 |
Why?
| Primary Prevention | 1 | 2014 | 185 | 0.110 |
Why?
| Pancreas, Artificial | 1 | 2013 | 71 | 0.110 |
Why?
| Kidney Transplantation | 1 | 2018 | 585 | 0.110 |
Why?
| Sulfhydryl Compounds | 1 | 2014 | 179 | 0.110 |
Why?
| Polymorphism, Genetic | 1 | 2015 | 642 | 0.100 |
Why?
| Alum Compounds | 1 | 2011 | 22 | 0.100 |
Why?
| Skin Neoplasms | 1 | 2018 | 762 | 0.100 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 304 | 0.100 |
Why?
| Small Molecule Libraries | 1 | 2011 | 80 | 0.100 |
Why?
| Cytokines | 2 | 2017 | 1900 | 0.100 |
Why?
| Dendritic Cells | 1 | 2014 | 442 | 0.100 |
Why?
| Thyroglobulin | 1 | 2010 | 18 | 0.090 |
Why?
| Structure-Activity Relationship | 1 | 2011 | 522 | 0.090 |
Why?
| Dietary Proteins | 1 | 2011 | 130 | 0.090 |
Why?
| Whole Body Imaging | 1 | 2010 | 25 | 0.090 |
Why?
| Thyroidectomy | 1 | 2010 | 54 | 0.090 |
Why?
| Radionuclide Imaging | 1 | 2010 | 124 | 0.090 |
Why?
| Iodine Radioisotopes | 1 | 2010 | 130 | 0.090 |
Why?
| Iatrogenic Disease | 1 | 2010 | 49 | 0.090 |
Why?
| Diagnosis, Differential | 1 | 2014 | 1384 | 0.090 |
Why?
| Self Tolerance | 1 | 2009 | 28 | 0.090 |
Why?
| Immune Tolerance | 1 | 2011 | 334 | 0.090 |
Why?
| Organ Specificity | 1 | 2010 | 278 | 0.090 |
Why?
| Hysterectomy | 1 | 2010 | 117 | 0.090 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2014 | 1244 | 0.080 |
Why?
| Adrenal Insufficiency | 1 | 2009 | 30 | 0.080 |
Why?
| Mice, Inbred BALB C | 1 | 2011 | 1206 | 0.080 |
Why?
| Interferon-alpha | 1 | 2010 | 191 | 0.080 |
Why?
| Interleukin-2 | 1 | 2010 | 416 | 0.080 |
Why?
| Sensitivity and Specificity | 3 | 2019 | 1795 | 0.080 |
Why?
| Syndrome | 1 | 2009 | 344 | 0.080 |
Why?
| Mice, Inbred C57BL | 2 | 2017 | 4908 | 0.070 |
Why?
| Vaccines | 1 | 2011 | 380 | 0.070 |
Why?
| Gene Expression Regulation | 1 | 2015 | 2445 | 0.070 |
Why?
| Area Under Curve | 2 | 2016 | 296 | 0.070 |
Why?
| Histocompatibility Testing | 2 | 2017 | 123 | 0.070 |
Why?
| Leukocytes, Mononuclear | 2 | 2019 | 509 | 0.070 |
Why?
| Risk Assessment | 1 | 2014 | 3057 | 0.060 |
Why?
| Prospective Studies | 3 | 2023 | 6471 | 0.060 |
Why?
| Cell Differentiation | 2 | 2022 | 1753 | 0.060 |
Why?
| Perilipin-1 | 1 | 2023 | 16 | 0.060 |
Why?
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2022 | 11 | 0.060 |
Why?
| Models, Biological | 1 | 2010 | 1715 | 0.060 |
Why?
| HLA-A2 Antigen | 1 | 2021 | 39 | 0.050 |
Why?
| Transcription Factors | 1 | 2009 | 1570 | 0.050 |
Why?
| Psychology, Child | 1 | 1981 | 36 | 0.050 |
Why?
| Seroepidemiologic Studies | 1 | 2021 | 146 | 0.050 |
Why?
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 94 | 0.050 |
Why?
| Neurologic Examination | 1 | 2000 | 126 | 0.050 |
Why?
| HLA-B15 Antigen | 1 | 2019 | 12 | 0.050 |
Why?
| NFATC Transcription Factors | 1 | 2020 | 82 | 0.040 |
Why?
| Hand Strength | 1 | 2000 | 99 | 0.040 |
Why?
| Genes, Reporter | 1 | 2020 | 270 | 0.040 |
Why?
| Psychotic Disorders | 1 | 1981 | 135 | 0.040 |
Why?
| Flow Cytometry | 2 | 2014 | 1085 | 0.040 |
Why?
| Hand | 1 | 2000 | 137 | 0.040 |
Why?
| Adoptive Transfer | 1 | 2019 | 204 | 0.040 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2020 | 170 | 0.040 |
Why?
| Genetic Vectors | 1 | 2020 | 302 | 0.040 |
Why?
| Phosphoproteins | 1 | 2021 | 308 | 0.040 |
Why?
| Adipose Tissue | 1 | 2023 | 606 | 0.040 |
Why?
| Antibody Specificity | 1 | 2018 | 184 | 0.040 |
Why?
| Cell- and Tissue-Based Therapy | 1 | 2018 | 54 | 0.040 |
Why?
| Gene Editing | 1 | 2018 | 63 | 0.040 |
Why?
| Cohort Studies | 2 | 2018 | 5116 | 0.040 |
Why?
| Immunization | 1 | 2020 | 412 | 0.040 |
Why?
| Lymphocytes | 1 | 2019 | 347 | 0.040 |
Why?
| Molecular Dynamics Simulation | 1 | 2019 | 213 | 0.040 |
Why?
| Stem Cell Transplantation | 1 | 2018 | 153 | 0.040 |
Why?
| Gene Frequency | 1 | 2018 | 513 | 0.040 |
Why?
| Receptors, CXCR3 | 1 | 2016 | 16 | 0.040 |
Why?
| HEK293 Cells | 1 | 2019 | 625 | 0.040 |
Why?
| CD56 Antigen | 1 | 2016 | 34 | 0.040 |
Why?
| Receptors, IgG | 1 | 2016 | 67 | 0.040 |
Why?
| Zinc Transporter 8 | 1 | 2016 | 63 | 0.030 |
Why?
| Graft Survival | 1 | 2018 | 504 | 0.030 |
Why?
| Forkhead Transcription Factors | 1 | 2016 | 182 | 0.030 |
Why?
| Cation Transport Proteins | 1 | 2016 | 99 | 0.030 |
Why?
| Skin | 1 | 2019 | 657 | 0.030 |
Why?
| Prevalence | 1 | 2021 | 2326 | 0.030 |
Why?
| Overweight | 1 | 2018 | 502 | 0.030 |
Why?
| T-Lymphocyte Subsets | 1 | 2016 | 396 | 0.030 |
Why?
| Chromatography, Ion Exchange | 1 | 2014 | 51 | 0.030 |
Why?
| Single-Blind Method | 1 | 2014 | 269 | 0.030 |
Why?
| Gastrins | 1 | 2013 | 8 | 0.030 |
Why?
| Colesevelam Hydrochloride | 1 | 2013 | 7 | 0.030 |
Why?
| Chromatography, Gel | 1 | 2014 | 133 | 0.030 |
Why?
| Allylamine | 1 | 2013 | 7 | 0.030 |
Why?
| Bromocriptine | 1 | 2013 | 28 | 0.030 |
Why?
| Sodium-Glucose Transporter 1 | 1 | 2013 | 12 | 0.030 |
Why?
| Dimerization | 1 | 2014 | 183 | 0.030 |
Why?
| Sodium-Glucose Transporter 2 | 1 | 2013 | 21 | 0.030 |
Why?
| Drug Combinations | 1 | 2014 | 291 | 0.030 |
Why?
| Risk Factors | 2 | 2018 | 9000 | 0.030 |
Why?
| Surface Plasmon Resonance | 1 | 2014 | 85 | 0.030 |
Why?
| Killer Cells, Natural | 1 | 2016 | 381 | 0.030 |
Why?
| Sulfonylurea Compounds | 1 | 2013 | 44 | 0.030 |
Why?
| Risk | 1 | 2016 | 853 | 0.030 |
Why?
| Cells, Cultured | 1 | 2021 | 4077 | 0.030 |
Why?
| Islet Amyloid Polypeptide | 1 | 2013 | 47 | 0.030 |
Why?
| Toll-Like Receptors | 1 | 2014 | 167 | 0.030 |
Why?
| Primary Cell Culture | 1 | 2013 | 155 | 0.030 |
Why?
| Proportional Hazards Models | 1 | 2016 | 1125 | 0.030 |
Why?
| Recombinant Proteins | 1 | 2016 | 1308 | 0.030 |
Why?
| Statistics, Nonparametric | 1 | 2014 | 403 | 0.030 |
Why?
| Glucagon-Like Peptide 1 | 1 | 2013 | 103 | 0.030 |
Why?
| Thiazolidinediones | 1 | 2013 | 146 | 0.030 |
Why?
| Leptin | 1 | 2013 | 231 | 0.030 |
Why?
| Reproducibility of Results | 1 | 2019 | 2874 | 0.030 |
Why?
| Baculoviridae | 1 | 2011 | 46 | 0.030 |
Why?
| Interleukin-1beta | 1 | 2014 | 379 | 0.030 |
Why?
| Diabetic Angiopathies | 1 | 2013 | 260 | 0.030 |
Why?
| Severity of Illness Index | 1 | 2019 | 2674 | 0.030 |
Why?
| Down-Regulation | 1 | 2014 | 627 | 0.020 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 332 | 0.020 |
Why?
| Oxidation-Reduction | 1 | 2014 | 940 | 0.020 |
Why?
| Thymus Gland | 1 | 2011 | 300 | 0.020 |
Why?
| Metformin | 1 | 2013 | 295 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2019 | 3730 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2016 | 2513 | 0.020 |
Why?
| Phenotype | 1 | 2017 | 3003 | 0.020 |
Why?
| Postoperative Complications | 1 | 2000 | 2235 | 0.020 |
Why?
| Gene Expression | 1 | 2013 | 1489 | 0.020 |
Why?
| Signal Transduction | 1 | 2020 | 4709 | 0.020 |
Why?
| Time Factors | 1 | 2016 | 6412 | 0.020 |
Why?
| Obesity | 1 | 2018 | 2746 | 0.020 |
Why?
| Registries | 1 | 2013 | 1810 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2013 | 4552 | 0.010 |
Why?
| Aged, 80 and over | 1 | 2013 | 6561 | 0.010 |
Why?
| Cardiovascular Diseases | 1 | 2013 | 1798 | 0.010 |
Why?
| Language Development Disorders | 1 | 1981 | 40 | 0.010 |
Why?
| Mother-Child Relations | 1 | 1981 | 109 | 0.010 |
Why?
| Child Behavior Disorders | 1 | 1981 | 129 | 0.010 |
Why?
| United States | 1 | 2013 | 12555 | 0.010 |
Why?
| Family | 1 | 1981 | 585 | 0.010 |
Why?
| Communication | 1 | 1981 | 761 | 0.010 |
Why?
|
|
Michels's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|